FDA 483 - Octapharma Pharmazeutika Produktionsgesellschaft m.b.H.
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Octapharma Pharmazeutika Produktionsgesellschaft m.b.H. OPG, a biologics blood product manufacturer in Vienna, Austria, was cited for significant cGMP deficiencies during an FDA inspection. Observations included inadequate facility maintenance and pest control, ineffective employee training and deviation investigations, and unjustified material holding times. Additionally, the firm failed to properly store reference standards, verify CAPAs effectively, adequately investigate Out of Specification results for measles antibody levels, and ensure data integrity for archived records.
- Product Type
- Biologics
ID · 41317198-3cd8-4a71-afdd-55abf08b281b